Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas. (CHARTHER)

Andrés José Maria Ferreri

Status: Completed

Conditions: Diffuse Large B Cell Lymphoma (DLBCL)

Treatments: Combination Product: Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT07181785

CHARTHER

Details and patient eligibility

About

This is a retrospective analysis of the presence of chromosomal rearrangements involving MYC, BCL2 and BCL6 genes by FISH in a retrospective, single-center series of large B-cell lymphomas, in order to allow a better classifications of these cases according to the current WHO 2017 classification. If this evaluation will be confirmed as a reliable method to reclassify in different groups the evaluated tumors, it can be subsequently routinely apply to indicate the best treatment approaches in this high-risk setting of patients with a significant impact on patients' morbidity and mortality, and also on the health system and related costs.

Enrollment: 555 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Histologically-confirmed diagnosis of LBCL (i.e., DLBCL, HGBCL, unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL), or aggressive B-cell lymphomas with blastoid morphology (excluding blastoid variant of mantle cell lymphoma and lymphoblastic lymphoma)
• Histopathological diagnosis performed between 2000 and 2019.
• HIV sero-negativity
• Age ≥18
• Treatment with R-CHOP or other intensified polychemotherapy regimen
• Availability of adequate histopathological samples at diagnosis for FISH analysis
• Availability of clinical records and outcomes data

Exclusion criteria

• Histologic diagnosis other than DLBCL or unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL

Trial design

555 participants in 1 patient group

Adult subjects (> 18 years old) of any age and gender affected by large B-cell lymphoma.

Description:

Histologically-confirmed diagnosis of LBCL (i.e., DLBCL, HGBCL, unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL), or aggressive B-cell lymphomas with blastoid morphology (excluding blastoid variant of mantle cell lymphoma and lymphoblastic lymphoma) * Histopathological diagnosis performed between 2000 and 2019. * HIV sero-negativity * Age ≥18 * Treatment with R-CHOP or other intensified polychemotherapy regimen * Availability of adequate histopathological samples at diagnosis for FISH analysis * Availability of clinical records and outcomes data

Treatment:

Combination Product: Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy